WO2022220288A1 - 組成物、安定化方法、および、発光量を測定する方法、ならびに、発光基質用安定化剤 - Google Patents
組成物、安定化方法、および、発光量を測定する方法、ならびに、発光基質用安定化剤 Download PDFInfo
- Publication number
- WO2022220288A1 WO2022220288A1 PCT/JP2022/017860 JP2022017860W WO2022220288A1 WO 2022220288 A1 WO2022220288 A1 WO 2022220288A1 JP 2022017860 W JP2022017860 W JP 2022017860W WO 2022220288 A1 WO2022220288 A1 WO 2022220288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- atom
- solution
- luminescent substrate
- luminescence
- transition metal
- Prior art date
Links
- 239000000758 substrate Substances 0.000 title claims abstract description 235
- 238000004020 luminiscence type Methods 0.000 title claims abstract description 159
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 238000000034 method Methods 0.000 title claims abstract description 70
- 239000003381 stabilizer Substances 0.000 title claims abstract description 25
- 238000011105 stabilization Methods 0.000 title claims description 22
- 230000006641 stabilisation Effects 0.000 title claims description 21
- 150000003623 transition metal compounds Chemical class 0.000 claims abstract description 109
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 19
- 150000003682 vanadium compounds Chemical class 0.000 claims abstract description 19
- 150000002822 niobium compounds Chemical class 0.000 claims abstract description 17
- 150000003482 tantalum compounds Chemical class 0.000 claims abstract description 17
- 239000003054 catalyst Substances 0.000 claims description 41
- 239000002253 acid Substances 0.000 claims description 39
- 230000003647 oxidation Effects 0.000 claims description 39
- 238000007254 oxidation reaction Methods 0.000 claims description 39
- 239000007800 oxidant agent Substances 0.000 claims description 34
- 239000000126 substance Substances 0.000 claims description 30
- 229910052783 alkali metal Inorganic materials 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 28
- -1 alkali metal salt Chemical class 0.000 claims description 23
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical group [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 18
- 229910052720 vanadium Inorganic materials 0.000 claims description 17
- 150000001340 alkali metals Chemical group 0.000 claims description 16
- 229910052715 tantalum Inorganic materials 0.000 claims description 16
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical group [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 16
- 229910052758 niobium Inorganic materials 0.000 claims description 15
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical group [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 claims description 15
- 150000003863 ammonium salts Chemical class 0.000 claims description 12
- XDBSEZHMWGHVIL-UHFFFAOYSA-M hydroxy(dioxo)vanadium Chemical compound O[V](=O)=O XDBSEZHMWGHVIL-UHFFFAOYSA-M 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- ABEDICJFYSFCHB-UHFFFAOYSA-N 8-amino-5-chloro-7-phenyl-2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione Chemical compound N1=C(Cl)C(C(NNC2=O)=O)=C2C(N)=C1C1=CC=CC=C1 ABEDICJFYSFCHB-UHFFFAOYSA-N 0.000 claims description 5
- 239000000243 solution Substances 0.000 description 273
- 239000003153 chemical reaction reagent Substances 0.000 description 112
- 238000005259 measurement Methods 0.000 description 92
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical class O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 69
- 238000003860 storage Methods 0.000 description 45
- 102000003992 Peroxidases Human genes 0.000 description 42
- 108040007629 peroxidase activity proteins Proteins 0.000 description 42
- 239000000872 buffer Substances 0.000 description 37
- 239000006249 magnetic particle Substances 0.000 description 33
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 32
- 230000007423 decrease Effects 0.000 description 30
- 239000003623 enhancer Substances 0.000 description 29
- 102000011923 Thyrotropin Human genes 0.000 description 28
- 108010061174 Thyrotropin Proteins 0.000 description 28
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 27
- 238000000691 measurement method Methods 0.000 description 26
- 239000000654 additive Substances 0.000 description 25
- 239000007853 buffer solution Substances 0.000 description 25
- 230000000052 comparative effect Effects 0.000 description 25
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 24
- 239000004327 boric acid Substances 0.000 description 24
- 239000013076 target substance Substances 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 21
- 230000035945 sensitivity Effects 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 16
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 15
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 14
- 239000011734 sodium Substances 0.000 description 13
- 229910052708 sodium Inorganic materials 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 10
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 10
- 230000000996 additive effect Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- ALTWGIIQPLQAAM-UHFFFAOYSA-N metavanadate Chemical compound [O-][V](=O)=O ALTWGIIQPLQAAM-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- RPESBQCJGHJMTK-UHFFFAOYSA-I pentachlorovanadium Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[V+5] RPESBQCJGHJMTK-UHFFFAOYSA-I 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 8
- 230000006866 deterioration Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 8
- 229910052700 potassium Inorganic materials 0.000 description 8
- 239000011591 potassium Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical group [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 229910052744 lithium Inorganic materials 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 6
- UNTBPXHCXVWYOI-UHFFFAOYSA-O azanium;oxido(dioxo)vanadium Chemical compound [NH4+].[O-][V](=O)=O UNTBPXHCXVWYOI-UHFFFAOYSA-O 0.000 description 6
- 229910052792 caesium Inorganic materials 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 5
- HSXUNHYXJWDLDK-UHFFFAOYSA-N 2-hydroxypropane-1-sulfonic acid Chemical compound CC(O)CS(O)(=O)=O HSXUNHYXJWDLDK-UHFFFAOYSA-N 0.000 description 5
- ZDXNEAWEPCZBQO-UHFFFAOYSA-N 4-(1,3-thiazol-4-yl)phenol Chemical compound C1=CC(O)=CC=C1C1=CSC=N1 ZDXNEAWEPCZBQO-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 235000010724 Wisteria floribunda Nutrition 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 4
- 229910003206 NH4VO3 Inorganic materials 0.000 description 4
- 229910017715 NH4VO4 Inorganic materials 0.000 description 4
- 229910019501 NaVO3 Inorganic materials 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 229910001172 neodymium magnet Inorganic materials 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 240000003291 Armoracia rusticana Species 0.000 description 3
- 235000011330 Armoracia rusticana Nutrition 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 229910021144 KVO3 Inorganic materials 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910020700 Na3VO4 Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229910021550 Vanadium Chloride Inorganic materials 0.000 description 3
- 230000003208 anti-thyroid effect Effects 0.000 description 3
- 229940043671 antithyroid preparations Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- DSYRJFDOOSKABR-UHFFFAOYSA-I niobium(v) bromide Chemical compound [Br-].[Br-].[Br-].[Br-].[Br-].[Nb+5] DSYRJFDOOSKABR-UHFFFAOYSA-I 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- RVJVDCVIJCBUTH-UHFFFAOYSA-M sodium;5-amino-2h-phthalazin-3-ide-1,4-dione Chemical class [Na+].O=C1N[N-]C(=O)C2=C1C(N)=CC=C2 RVJVDCVIJCBUTH-UHFFFAOYSA-M 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000007979 thiazole derivatives Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- PAJMKGZZBBTTOY-UHFFFAOYSA-N 2-[[2-hydroxy-1-(3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1h-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid Chemical compound C1=CC=C(OCC(O)=O)C2=C1CC1C(CCC(O)CCCCC)C(O)CC1C2 PAJMKGZZBBTTOY-UHFFFAOYSA-N 0.000 description 2
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 102100035882 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
- YNLCVAQJIKOXER-UHFFFAOYSA-N N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid Chemical compound OCC(CO)(CO)NCCCS(O)(=O)=O YNLCVAQJIKOXER-UHFFFAOYSA-N 0.000 description 2
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- QKDGGEBMABOMMW-UHFFFAOYSA-I [OH-].[OH-].[OH-].[OH-].[OH-].[V+5] Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[V+5] QKDGGEBMABOMMW-UHFFFAOYSA-I 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000010955 niobium Substances 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- XXQBEVHPUKOQEO-UHFFFAOYSA-N potassium superoxide Chemical compound [K+].[K+].[O-][O-] XXQBEVHPUKOQEO-UHFFFAOYSA-N 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- ZOYIPGHJSALYPY-UHFFFAOYSA-K vanadium(iii) bromide Chemical compound [V+3].[Br-].[Br-].[Br-] ZOYIPGHJSALYPY-UHFFFAOYSA-K 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DIEJWUNVACYJEZ-UHFFFAOYSA-N 1-(1h-imidazol-5-yl)imidazole Chemical class C1=NC=CN1C1=CNC=N1 DIEJWUNVACYJEZ-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- FWSCKHWSVNTKRH-UHFFFAOYSA-N 1-bromo-2h-naphthalen-1-ol Chemical compound C1=CC=C2C(O)(Br)CC=CC2=C1 FWSCKHWSVNTKRH-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- VUODUOODVVUDMV-UHFFFAOYSA-N 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid Chemical compound OCC(CO)(CO)NCC(O)=O.OCC(CO)(CO)NCC(O)=O VUODUOODVVUDMV-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- QMIPCYMONNSFTD-UHFFFAOYSA-N 4-(1,3-oxazol-4-yl)phenol Chemical class C1=CC(O)=CC=C1C1=COC=N1 QMIPCYMONNSFTD-UHFFFAOYSA-N 0.000 description 1
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 1
- 229940046305 5-bromo-5-nitro-1,3-dioxane Drugs 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- BEADQYOTAORBKI-UHFFFAOYSA-N 6-[6-aminohexyl(ethyl)amino]-2,3-dihydrophthalazine-1,4-dione Chemical compound O=C1NNC(=O)C=2C1=CC(N(CCCCCCN)CC)=CC=2 BEADQYOTAORBKI-UHFFFAOYSA-N 0.000 description 1
- JMHFFDIMOUKDCZ-NTXHZHDSSA-N 61214-51-5 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 JMHFFDIMOUKDCZ-NTXHZHDSSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102400001364 Alpha-1-microglobulin Human genes 0.000 description 1
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 1
- 102400000748 Beta-endorphin Human genes 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229910017458 CsVO3 Inorganic materials 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000013271 Hemopexin Human genes 0.000 description 1
- 108010026027 Hemopexin Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 229910003334 KNbO3 Inorganic materials 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 229910012599 Li3NbO4 Inorganic materials 0.000 description 1
- 229910003327 LiNbO3 Inorganic materials 0.000 description 1
- 229910012985 LiVO3 Inorganic materials 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910003378 NaNbO3 Inorganic materials 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100038358 Prostate-specific antigen Human genes 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000030452 Transient pseudohypoaldosteronism Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- XVBRCOKDZVQYAY-UHFFFAOYSA-N bronidox Chemical compound [O-][N+](=O)C1(Br)COCOC1 XVBRCOKDZVQYAY-UHFFFAOYSA-N 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000012767 chemiluminescent enzyme immunoassay Methods 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
- 229940119740 deoxycorticosterone Drugs 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- CCAFPWNGIUBUSD-UHFFFAOYSA-N diethyl sulfoxide Chemical compound CCS(=O)CC CCAFPWNGIUBUSD-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AXZAYXJCENRGIM-UHFFFAOYSA-J dipotassium;tetrabromoplatinum(2-) Chemical compound [K+].[K+].[Br-].[Br-].[Br-].[Br-].[Pt+2] AXZAYXJCENRGIM-UHFFFAOYSA-J 0.000 description 1
- BNBLBRISEAQIHU-UHFFFAOYSA-N disodium dioxido(dioxo)manganese Chemical compound [Na+].[Na+].[O-][Mn]([O-])(=O)=O BNBLBRISEAQIHU-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229960002972 glutethimide Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940109738 hematin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000005453 ketone based solvent Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 150000002641 lithium Chemical group 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 150000004780 naphthols Chemical class 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- VPDYSPXEGTXWEU-UHFFFAOYSA-K niobium(3+);trichloride Chemical compound Cl[Nb](Cl)Cl VPDYSPXEGTXWEU-UHFFFAOYSA-K 0.000 description 1
- WPCMRGJTLPITMF-UHFFFAOYSA-I niobium(5+);pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Nb+5] WPCMRGJTLPITMF-UHFFFAOYSA-I 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- YHBDIEWMOMLKOO-UHFFFAOYSA-I pentachloroniobium Chemical compound Cl[Nb](Cl)(Cl)(Cl)Cl YHBDIEWMOMLKOO-UHFFFAOYSA-I 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- LLYCMZGLHLKPPU-UHFFFAOYSA-N perbromic acid Chemical compound OBr(=O)(=O)=O LLYCMZGLHLKPPU-UHFFFAOYSA-N 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229910001487 potassium perchlorate Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- VXLUZERCXISKBW-UHFFFAOYSA-M potassium;perbromate Chemical compound [K+].[O-]Br(=O)(=O)=O VXLUZERCXISKBW-UHFFFAOYSA-M 0.000 description 1
- 229960000249 pregnenolone Drugs 0.000 description 1
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 1
- 229960002060 secobarbital Drugs 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 125000004436 sodium atom Chemical group 0.000 description 1
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
- 229910001488 sodium perchlorate Inorganic materials 0.000 description 1
- MUPJWXCPTRQOKY-UHFFFAOYSA-N sodium;niobium(5+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Na+].[Nb+5] MUPJWXCPTRQOKY-UHFFFAOYSA-N 0.000 description 1
- CLURAKRVQIPBCC-UHFFFAOYSA-M sodium;perbromate Chemical compound [Na+].[O-]Br(=O)(=O)=O CLURAKRVQIPBCC-UHFFFAOYSA-M 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 229960002573 sultiame Drugs 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- ZIRLXLUNCURZTP-UHFFFAOYSA-I tantalum(5+);pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[Ta+5] ZIRLXLUNCURZTP-UHFFFAOYSA-I 0.000 description 1
- GCPVYIPZZUPXPB-UHFFFAOYSA-I tantalum(v) bromide Chemical compound Br[Ta](Br)(Br)(Br)Br GCPVYIPZZUPXPB-UHFFFAOYSA-I 0.000 description 1
- OEIMLTQPLAGXMX-UHFFFAOYSA-I tantalum(v) chloride Chemical compound Cl[Ta](Cl)(Cl)(Cl)Cl OEIMLTQPLAGXMX-UHFFFAOYSA-I 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- GEVPIWPYWJZSPR-UHFFFAOYSA-N tcpo Chemical compound ClC1=CC(Cl)=CC(Cl)=C1OC(=O)C(=O)OC1=C(Cl)C=C(Cl)C=C1Cl GEVPIWPYWJZSPR-UHFFFAOYSA-N 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- CMVSVXQSGZAWHD-UHFFFAOYSA-J tetrabromotantalum Chemical compound Br[Ta](Br)(Br)Br CMVSVXQSGZAWHD-UHFFFAOYSA-J 0.000 description 1
- FCLAPXQWWIRXCV-UHFFFAOYSA-J tetrachloroniobium Chemical compound Cl[Nb](Cl)(Cl)Cl FCLAPXQWWIRXCV-UHFFFAOYSA-J 0.000 description 1
- JYIFRKSFEGQVTG-UHFFFAOYSA-J tetrachlorotantalum Chemical compound Cl[Ta](Cl)(Cl)Cl JYIFRKSFEGQVTG-UHFFFAOYSA-J 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- DPFMNIQJGWQWGJ-UHFFFAOYSA-K tribromotantalum Chemical compound Br[Ta](Br)Br DPFMNIQJGWQWGJ-UHFFFAOYSA-K 0.000 description 1
- UDKRLEXYBPHRQF-UHFFFAOYSA-K trichlorotantalum Chemical compound Cl[Ta](Cl)Cl UDKRLEXYBPHRQF-UHFFFAOYSA-K 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
- C09K11/07—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials having chemically interreactive components, e.g. reactive chemiluminescent compositions
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/02—Use of particular materials as binders, particle coatings or suspension media therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1011—Condensed systems
Definitions
- the present invention relates to a composition containing a luminescent substrate and a transition metal compound selected from a vanadium compound, a niobium compound, or a tantalum compound, a method for stabilizing the luminescent substrate, a method for measuring the amount of luminescence, and a stabilizer for the luminescent substrate. .
- chemiluminescence reactions are capable of highly sensitive measurements
- research is being actively carried out as a measurement system in the field of immunology.
- a representative measurement method there is a method of reacting an antigen or an antibody labeled with an enzyme such as peroxidase with a luminol derivative such as luminol or isoluminol, which is a chemiluminescent substance, and measuring the amount of luminescence.
- Luminol and luminol derivatives are widely used as compounds with excellent chemiluminescence quantum yield, since it is necessary to detect the target substance with high sensitivity for quantification of substances that exist only in minute amounts in vivo.
- a borate buffer is used as a luminescence reagent containing a luminol derivative (for example, Patent Document 1).
- boric acid has been reported to have reproductive toxicity, so it is desirable not to use boric acid in consideration of its effects on the human body and the environment.
- boric acid contributes to the stabilization of luminol derivatives, and when boric acid is not used, the amount of luminescence decreases due to changes over time, and the performance of the luminescent reagent in solution cannot be maintained. It turned out to be difficult.
- the present invention has been made in view of the above circumstances, and provides a composition capable of improving the stability of a luminescence reagent containing a luminescence substrate such as a luminol derivative in a solution state, thereby providing a stabilized luminescence reagent and the like. to do.
- the present invention consists of the following configurations.
- a composition containing a transition metal compound selected from vanadium compounds, niobium compounds and tantalum compounds and a luminescent substrate (hereinafter sometimes abbreviated as the composition of the present invention).
- the transition metal compound is a compound represented by general formula (1) or general formula (2).
- Z 1 represents a vanadium atom, a niobium atom or a tantalum atom
- M 1 represents a hydrogen atom, an alkali metal atom or NH 4
- each M 2 independently represents a hydrogen represents an atom, an alkali metal atom or NH4, m represents 0 or 1, n represents 2 when m is 0, and 0 when m is 1.
- Z 2 represents a vanadium atom, a niobium atom or a tantalum atom
- X 1 represents a hydroxy group, a chlorine atom or a bromine atom
- p represents an integer of 2 to 5.
- composition according to (3) above which contains the compound represented by the general formula (1) and a luminescent substrate.
- the compound represented by the general formula (1) is orthovanadic acid, an alkali metal salt of orthovanadic acid, an ammonium salt of orthovanadic acid, metavanadic acid, an alkali metal salt of metavanadic acid, or an ammonium salt of metavanadic acid.
- the luminescent substrate is a luminol, a chemically acceptable salt, or 8-amino-5-chloro-7-phenylpyrido[3,4-d]pyridazine-1,4(2H,3H)-dione Or the composition according to any one of (1) to (6) above, which is a chemically acceptable salt.
- composition according to any one of (1) to (9) above, wherein the composition has a pH of 5 to 12.
- a method for stabilizing a luminescent substrate (hereinafter sometimes abbreviated as the stabilization method of the present invention) in which a transition metal compound selected from vanadium compounds, niobium compounds, or tantalum compounds is allowed to coexist with the luminescent substrate.
- the transition metal compound is a compound represented by general formula (1) or general formula (2).
- Z 1 represents a vanadium atom, a niobium atom or a tantalum atom
- M 1 represents a hydrogen atom, an alkali metal atom or NH 4
- each M 2 independently represents a hydrogen represents an atom, an alkali metal atom or NH4, m represents 0 or 1, n represents 2 when m is 0, and 0 when m is 1.
- Z 2 represents a vanadium atom, a niobium atom or a tantalum atom
- X 1 represents a hydroxy group, a chlorine atom or a bromine atom
- p represents an integer of 2 to 5.
- a stabilizer for a luminescent substrate comprising a transition metal compound selected from vanadium compounds, niobium compounds and tantalum compounds.
- composition and stabilization method of the present invention can improve the stability of the luminescent substrate by allowing the luminescent substrate to coexist with a transition metal compound selected from vanadium compounds, niobium compounds and tantalum compounds. This makes it possible to suppress a decrease in the amount of light emitted from the luminescent substrate (decrease in measurement sensitivity) due to decomposition, deterioration, or the like of the luminescent substrate.
- a luminescence substrate and an oxidation catalyst are reacted in the presence of a transition metal compound selected from vanadium compounds, niobium compounds, and tantalum compounds to measure the amount of luminescence derived from a target substance (substance to be measured). It is a method for measurement, and the stability of the luminescent substrate can be improved during the reaction and the measurement of the luminescence level, and the luminescence level derived from the target substance can be measured with high sensitivity and accuracy.
- FIG. 1 is a graph showing the ratio of luminescence intensity to 11° C. in the case of using a standard TSH solution with a TSH concentration of 0.05 ⁇ IU/mL among the results of Table 1 (Example 1 and Comparative Examples 1 and 2).
- FIG. 2 is a graph showing the ratio of light emission to 11° C. when using a standard TSH solution with a TSH concentration of 0.05 ⁇ IU/mL among the results in Table 2 (Examples 2 to 3 and Comparative Examples 1 to 4). .
- FIG. 2 is a graph showing the ratio of luminescence intensity to 11° C.
- FIG. 4 is a graph showing the ratio of luminescence intensity to 11° C. when using a standard TSH solution with a TSH concentration of 0.05 ⁇ IU/mL among the results of Table 3 (Examples 4 to 6 and Comparative Examples 1 and 2). .
- FIG. 4 is a graph showing the ratio of luminescence intensity to 11° C. when using a standard TSH solution with a TSH concentration of 0.05 ⁇ IU/mL among the results of Table 4 (Examples 7 to 9 and Comparative Examples 1 and 2).
- the ratio of luminescence intensity to 11° C. when using a standard TSH solution with a TSH concentration of 0.05 ⁇ IU/mL was graphed. It is a diagram.
- FIG. 4 is a graph showing the ratio of luminescence intensity to 11° C. in the case of using a standard TSH solution with a TSH concentration of 0.05 ⁇ IU/mL among the results of Table 6 (Examples 11 to 13).
- composition of the present invention contains a transition metal compound selected from vanadium compounds, niobium compounds and tantalum compounds (hereinafter sometimes abbreviated as the transition metal compound according to the present invention) and a luminescent substrate.
- the transition metal compound according to the present invention a transition metal compound selected from vanadium compounds, niobium compounds and tantalum compounds
- the action of the transition metal compound suppresses decomposition and deterioration of the luminescent substrate.
- the composition of the present invention can be used to measure target substances in living organisms with high sensitivity and accuracy.
- the transition metal compound according to the present invention refers to a vanadium compound containing vanadium element in the compound, a niobium compound containing niobium element in the compound, and a tantalum compound containing tantalum element in the compound.
- Preferred specific examples of such transition metal compounds include compounds represented by general formula (1) or general formula (2).
- Z 1 represents a vanadium atom, a niobium atom or a tantalum atom
- M 1 represents a hydrogen atom, an alkali metal atom or NH 4
- each M 2 independently represents a hydrogen represents an atom, an alkali metal atom or NH4, m represents 0 or 1, n represents 2 when m is 0, and 0 when m is 1.
- Z 2 represents a vanadium atom, a niobium atom or a tantalum atom
- X 1 represents a hydroxy group, a chlorine atom or a bromine atom
- p represents an integer of 2 to 5.
- examples of the alkali metal atoms represented by M1 and M2 include a lithium atom, a sodium atom, a potassium atom and a cesium atom. Preferred are sodium and potassium atoms.
- Z 1 in general formula (1) and Z 2 in general formula (2) are preferably vanadium atoms and tantalum atoms, more preferably vanadium atoms.
- an alkali metal atom and NH4 are preferred, and NH4 is more preferred.
- M2 in general formula (1) may be the same group or different groups.
- n in general formula (1) is 0, it means that the (-OM 2 ) n group does not exist.
- X 1 in general formula (2) is preferably a chlorine atom or a bromine atom, more preferably a chlorine atom.
- p in the general formula (1) is preferably an integer of 3 to 5, preferably 3 and 5, more preferably 3.
- Examples of the compounds represented by formulas (1) and (2) include orthovanadate (V) (H 3 VO 4 ); lithium orthovanadate (V), (Li 3 VO 4 ), sodium orthovanadate (V) (Na 3 VO 4 ), potassium orthovanadate (V) (K 3 VO 4 ), cesium orthovanadate (V) (Cs 3 VO 4 ), etc.
- Alkali metal salts ammonium salts of orthovanadate such as ammonium orthovanadate (V) ( NH4VO4 ); metavanadate ( V) ( HVO3 ); lithium metavanadate (V) ( LiVO3 ), metavanadate ( V) alkali metal salts of metavanadate such as sodium ( NaVO3 ), potassium metavanadate (V) ( KVO3 ), cesium metavanadate (V) ( CsVO3 ); ammonium metavanadate (V) ( NH4VO3 ) ammonium salts of metavanadic acid such as; orthoniobate (V) ( H3NbO4 ); lithium orthoniobate ( V) ( Li3NbO4 ), sodium ) alkali metal salts of orthoniobate such as potassium ( K3NbO4 ), cesium (V) orthoniobate ( Cs3NbO4 ); ammonium salts of orthoniobate such as ammoni
- transition metal compounds according to the present invention compounds represented by the above general formula (1) are preferred, and among others, compounds represented by the following general formula (1-1) are more preferred.
- M 1 , M 2 , m and n are the same as M 1 , M 2 , m and n in formula (1) above.
- Specific examples of the compound represented by the general formula (1-1) include orthovanadic acid (V) (H 3 VO 4 ), alkali metal salts of orthovanadic acid, and ammonium salts of orthovanadic acid. , metavanadic acid (V) (HVO 3 ), alkali metal salts of metavanadic acid, ammonium salts of metavanadic acid, etc.
- these preferable vanadic acids are less likely to adversely affect the measurement results during measurement, and can more effectively improve the stability of the luminescent substrate, thereby achieving the desired results with high accuracy. It has the effect of being able to measure things.
- one transition metal compound may be used alone, or two or more compounds may be used in combination.
- the luminescent substrate according to the composition of the present invention refers to a luminescent substance used for chemiluminescence measurement of a target substance, and is not particularly limited as long as it is a luminescent substrate (luminescent substance) used in this field.
- chemiluminescence measurement the presence and amount of the target substance is detected by detecting the chemiluminescence emitted by the chemiluminescent substance produced when the luminescent substrate (luminescent substance) is decomposed by the labeling enzyme.
- substrates that emit light by radicalization of the luminescent substrate are preferred, and specific examples include luminol, isoluminol, N-ethylisoluminol, N-(4-aminobutyl)- Luminols such as N-ethylisoluminol hemisuccimide, N-(6-aminohexyl)-N-ethylisoluminol, or chemically acceptable salts of luminols (alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as magnesium salts and calcium salts; ammonium salts, etc.); 8-amino-5-chloro-7-phenylpyrido[3,4-d]pyridazine-1,4(2H,3H)-dione (L -012) or a chemically acceptable salt of L-012; lucigenin; luciferin (firefly luciferin
- chemically acceptable salts of L-012 include, for example, salts described in International Publication No. 2017/069192.
- luminescent substrates include, for example, salts described in International Publication No. 2017/069192.
- luminescent substrates include, for example, salts described in International Publication No. 2017/069192.
- luminescent substrates include, for example, salts described in International Publication No. 2017/069192.
- luminols and chemically acceptable salts thereof are preferred, luminol, isoluminol and chemically acceptable salts thereof are more preferred, and luminol and chemically acceptable luminols are preferred. more preferred.
- commercially available ones may be used, or ones synthesized as appropriate by a method known per se may be used.
- composition of the present invention may be in a solution state, a frozen state, or a lyophilized state.
- a dissolving solution for dissolving the transition metal compound and the luminescent substrate of the present invention.
- a dissolution liquid is not particularly limited as long as it is a dissolution liquid used in this field, and specific examples thereof include water, buffer solutions, and the like.
- the buffer solution used in the composition method of the present invention is not particularly limited as long as it is a buffer solution used in this field.
- N-cyclohexyl-2-aminoethanesulfonic acid (CHES), 3-[4-(2-hydroxyethyl)-1-piperazinyl]propanesulfonic acid (EPPS), piperazine-1
- a buffer solution in which 4-bis(2-hydroxy-3-propanesulfonic acid) (POPSO), tris(hydroxymethyl)aminomethane (Tris) or diethanolamine or a salt thereof is dissolved is preferred
- N-cyclohexyl-2-amino ethanesulfonic acid (CHES), 3-[4-(2-hydroxyethyl)-1-piperazinyl]propanesulfonic acid (EPPS), piperazine-1,4-bis(2-hydroxy-3-propanesulfonic acid) (POPSO) ) or tris(hydroxymethyl)aminomethane (Tris) or a buffer solution in which salts thereof are dissolved is more preferable.
- buffers may be used alone, or may be used in combination of two or more buffers.
- buffers sodium hydroxide, potassium hydroxide, etc.
- a buffer solution may be prepared by combining an alkali metal hydroxide or an acid such as hydrochloric acid or sulfuric acid.
- buffer combinations include N-cyclohexyl-2-aminoethanesulfonic acid (CHES)/sodium hydroxide buffer, 3-[4-(2-hydroxyethyl)-1-piperazinyl]propanesulfonic acid (EPPS)/sodium hydroxide buffer, piperazine-1,4-bis(2-hydroxy-3-propanesulfonic acid) (POPSO)/sodium hydroxide buffer, tris(hydroxymethyl)aminomethane (Tris)/hydroxide sodium buffer solution and the like.
- These buffers may be commercially available or appropriately prepared by a method known per se.
- the concentration of the buffering agent in the buffer in the composition of the present invention may be appropriately selected from the range of usually 10-500 mM, preferably 10-300 mM.
- the concentration of the luminescent substrate in the composition of the present invention may be appropriately selected from the concentration range used in the field of chemiluminescence measurement.
- the lower limit of the concentration of the luminescent substrate in solution is usually It is 0.01 mM or more, preferably 0.1 mM or more, more preferably 0.2 mM or more, and the upper limit is usually 20 mM or less, preferably 10 mM or less, more preferably 5 mM or less.
- the concentration of the transition metal compound in the composition of the present invention is not particularly limited as long as it can improve the stability of the luminescent substrate.
- the concentration of the coexisting luminescent substrate, etc. for example, when the concentration of the luminescent substrate is used as the standard, the concentration of the luminescent substrate in the solution is 1 mM.
- the concentration of the transition metal compound the lower limit is usually 0.0005 mM or more, preferably 0.005 mM or more, more preferably 0.05 mM or more, and still more preferably 0.1 mM, and the upper limit is usually 10 mM or less, preferably 0.1 mM.
- the lower limit of the concentration of the transition metal compound in the solution is usually 0.01 mM or higher, preferably 0.05 mM or higher, more preferably 0.1 mM or higher, still more preferably 0.25 mM, most preferably 0.05 mM or higher. It is 5 mM, and the upper limit is usually 10 mM or less, preferably 5 mM or less, more preferably 2.5 mM or less, still more preferably 1 mM or less.
- the pH of the composition of the present invention may be appropriately selected from the range of usually pH 5-12, preferably pH 6-11, more preferably pH 6.5-10.5.
- composition of the present invention When the composition of the present invention is in the form of a solution, it is desirable to add the transition metal compound of the present invention and the luminescent substrate to the solution described above so that the concentration range and the concentration ratio are as described above.
- the transition metal compound of the present invention and a luminescent substrate are added to the frozen stock solution or the freeze-dried stock solution so that the concentration ranges and concentration ratios described above are satisfied.
- composition of the present invention it is desirable to contain when preparing the composition of the present invention with a dissolution liquid, such as when dissolving the composition of the present invention in a frozen or freeze-dried state with a dissolution liquid or when diluting a composition of the present invention in a solution state with a dissolution liquid is prepared so that the transition metal compound and the luminescent substrate according to the present invention after preparation (after dissolution, after dilution, etc.) are in the concentration range and concentration ratio described above, respectively, the luminescent substrate in the composition after preparation Stability may also be improved.
- a dissolution liquid such as when dissolving the composition of the present invention in a frozen or freeze-dried state with a dissolution liquid or when diluting a composition of the present invention in a solution state with a dissolution liquid is prepared so that the transition metal compound and the luminescent substrate according to the present invention after preparation (after dissolution, after dilution, etc.) are in the concentration range and concentration ratio described above, respectively, the luminescent substrate in
- the composition of the present invention contains, in addition to the transition metal compound of the present invention, a luminescent substrate, and water or/and a buffer solution, for example, salts such as sodium chloride and magnesium chloride; preservatives such as sodium azide; maltose; Sugars such as sucrose and trehalose; 5-chloro-2-methyl-4-isothiazolin-3-one, 2-methyl-4-isothiazolin-3-one, 5-bromo-5-nitro-1,3-dioxane, ( +) preservatives such as -10-camphorsulfonic acid; stabilizers; sensitizers; surfactants; These additives may be commercially available ones, or may be appropriately synthesized by a method known per se. Also, the composition of the present invention desirably does not contain boric acid or its salts.
- stabilizers include those represented by formulas [3-1] to [3-12]. One of these stabilizers may be used alone, or two or more stabilizers may be used in combination. The stabilizer is not limited to those represented by formulas [3-1] to [3-12].
- Preferred specific examples of the above stabilizers and specific examples of stabilizers other than [3-1] to [3-12] above include compounds and salts thereof described in International Publication No. 2017/069192, etc. is mentioned.
- the above-mentioned sensitizer (enhancer) is not particularly limited as long as it is a sensitizer (enhancer) used in this field.
- 4-(imidazol-1-yl) imidazole derivatives such as phenol; 4-(4-hydroxyphenyl) oxazole derivatives such as oxazole; p-iodophenol, 4-hydroxycinnamic acid, 4- Phenol derivatives such as (4'-thiazolyl)phenol; naphthol derivatives such as 1-bromonaphthol; among others, thiazole derivatives such as 4-(4-hydroxyphenyl)thiazole are preferred.
- these sensitizers (enhancers) one type of sensitizer (enhancer) may be used alone, or two or more types of sensitizers (enhancers) may be used in combination.
- the amount of these additives to be added may be appropriately set within the range used in this field.
- the composition of the present invention may contain organic solvents for the purpose of improving the solubility of the above additives in water or buffers.
- organic solvents include alcohol solvents such as methanol and ethanol; ether solvents such as tetrahydrofuran and 1,4-dioxane; ketone solvents such as acetone and ethyl methyl ketone; dimethylformamide and diethyl.
- Amide solvents such as formamide; sulfoxide solvents such as dimethylsulfoxide and diethylsulfoxide; nitrile solvents such as acetonitrile;
- One type of these organic solvents may be used alone, or two or more types of solvents may be used in combination.
- the amount of these organic solvents to be used may be appropriately set in consideration of their solubility in water or buffer solution, their adverse effects on the chemiluminescence measurement described below, and the like.
- the composition of the present invention can improve the stability of the luminescent substrate in a solution state by allowing the transition metal compound of the present invention to coexist with the luminescent substrate. In measurement, it is possible to suppress a decrease in the amount of light emitted from the luminescent substrate (decrease in measurement sensitivity) due to decomposition or deterioration of the luminescent substrate, and to detect and measure the target substance with high accuracy.
- the stabilization method of the present invention is a method of coexisting a transition metal compound selected from vanadium compounds, niobium compounds and tantalum compounds in a luminescent substrate.
- a specific technique for the stabilization method of the present invention is not particularly limited as long as it is a method in which the transition metal compound of the present invention is allowed to coexist with a luminescent substrate.
- Examples of the luminescent substrate and the transition metal compound according to the present invention used in the stabilization method of the present invention include the same specific examples as the luminescent substrate and transition metal compound used in the composition of the present invention described above.
- the concentration used and the concentration ratio between the luminescent substrate and the transition metal compound are also the same as those described above.
- the dissolution solution used in the stabilization method of the present invention includes the same specific examples as the buffer solution used in the composition of the present invention described above, and preferred specific examples are also the same.
- the concentration of the buffering agent contained in the above buffer solution is also the same as the range described above.
- the pH of the solution in which the transition metal compound is allowed to coexist with the luminescent substrate includes the same range as the pH range of the composition of the present invention, and the preferred range is also the same.
- additives and organic solvents used in this field may coexist.
- examples of the organic solvent include the same specific examples of the additive and the organic solvent in the composition of the present invention, and the amount of the additive added and the amount of the organic solvent used are also as described above.
- the stabilization method of the present invention which is performed based on the above-described specific technique, stabilizes the luminescent substrate for a long period of time by suppressing the decomposition (deterioration) of the luminescent substrate, thereby reducing the amount of light emitted by the luminescent substrate (lowering the measurement sensitivity). ) can be suppressed.
- the transition metal compound of the present invention is less likely to adversely affect measurement when a solution containing the luminescent substrate is used. Substances can be measured.
- the measurement method of the present invention is a method of reacting a luminescent substrate, an oxidizing agent, and an oxidation catalyst in the coexistence of the transition metal compound of the present invention, and measuring the amount of luminescence. That is, the measurement method of the present invention is a method for measuring the luminescence reaction of a luminescent substrate and the amount of chemiluminescent substance generated thereby. By using the measuring method of the present invention, the presence or absence and amount of a target substance contained in a sample can be detected.
- the measurement method of the present invention include various methods known per se, such as a method of detecting and measuring chemiluminescence generated by a reaction (chemiluminescence reaction) between an oxidizing agent and a luminescent substrate.
- specific techniques for reacting a luminescent substrate, an oxidizing agent, and an oxidation catalyst include, for example, (1) a solution containing a luminescent substrate and the transition metal compound according to the present invention (luminescent substrate solution); (2) a solution containing a luminescent substrate and a transition metal compound according to the present invention (luminescent substrate solution), a solution containing an oxidation catalyst, and (3) a solution containing an oxidation catalyst, a solution containing a luminescent substrate and a transition metal compound according to the present invention (luminescent substrate solution), and a solution containing an oxidizing agent; (4) A solution containing an oxidation catalyst, a solution containing a luminescent substrate and the transition metal compound according to the present invention (luminescent substrate solution), and a solution containing an oxidizing agent are simultaneously mixed and reacted. There are methods, etc. These reactions are usually carried out in a solvent.
- the luminescent substrate and the transition metal compound according to the present invention used in the measurement method of the present invention include the same specific examples as the luminescent substrate and transition metal compound used in the composition of the present invention described above.
- the oxidation catalysts mentioned above refer to catalysts containing metals such as iron, cobalt, manganese, nickel, chromium, zinc, osmium, molybdenum, cadmium, or copper. not.
- oxidation catalysts include peroxidase (POD), oxidases such as catalase; hydrolases such as alkaline phosphatase; metalloporphyrin compounds such as cobalamin and hematin; hemproteins such as hemoglobin; (K 3 [Fe(CN) 6 ]) and the like, among which oxidases such as peroxidase (POD) and catalase are preferred, and peroxidase (POD) is more preferred.
- POD peroxidase
- POD peroxidase
- catalase hydrolases
- metalloporphyrin compounds such as cobalamin and hematin
- hemproteins such as hemoglobin
- K 3 [Fe(CN) 6 ] oxid
- the above-mentioned peroxidase (POD) is not particularly limited as long as it can chemiluminesce a luminescent substrate in the presence of an oxidizing agent such as hydrogen peroxide.
- an oxidizing agent such as hydrogen peroxide.
- those derived from plants such as horseradish, pineapple, and figs (horseradish peroxidase, etc.); those derived from microorganisms such as mold and yeast; peroxidase, etc.), among which those derived from horseradish (horseradish peroxidase) are preferred.
- Such peroxidase (POD) is produced by genetic engineering or obtained by hydrolyzing a part of the structure of naturally occurring peroxidase (POD) with a proteolytic enzyme or the like. , including those with POD activity.
- Peroxidase (POD) may also be bound to antigens, antibodies, and the like.
- oxidizing agents examples include hydrogen peroxide, sodium peroxide, potassium peroxide, perchloric acid, sodium perchlorate, potassium perchlorate, perbromic acid, sodium perbromate, potassium perbromate, Inorganic peroxides such as sodium manganate, potassium permanganate and iodine; Examples include organic peroxides, among which inorganic peroxides are preferred, hydrogen peroxide and sodium peroxide are more preferred, and hydrogen peroxide is even more preferred. Commercially available products may be used as these oxidizing agents.
- a sensitizer may be used in addition to the luminescent substrate, the transition metal compound of the present invention, the oxidation catalyst and the oxidizing agent.
- sensitizer examples include the same specific examples as the sensitizer (enhancer) used in the composition of the present invention, and preferred specific examples are also the same.
- the amount of the luminescent substrate used in the measurement method of the present invention may vary depending on the method of measurement, so it cannot be generalized. 0.01 to 20 mM and 5 ⁇ L to 1 mL, preferably 0.1 to 10 mM concentration and 10 to 500 ⁇ L, more preferably 0.2 to 5 mM concentration and 20 to 300 ⁇ L.
- the amount of the luminescent substrate to be used is usually 5 ⁇ L to 1 mL at a concentration of 0.01 to 20 mM, preferably 0.1, per 25 ⁇ L of the sample. It is 10-500 ⁇ L at ⁇ 10 mM, more preferably 20-300 ⁇ L at 0.2-5 mM concentration.
- the amount of the transition metal compound according to the present invention used in the measuring method of the present invention may vary depending on the mode of measurement, so it cannot be generalized. On the other hand, it is usually 5 ⁇ L to 1 mL at a concentration of 0.01 to 10 mM, preferably 10 to 500 ⁇ L at a concentration of 0.05 to 5 mM, more preferably 20 to 20 ⁇ L at a concentration of 0.1 to 2 mM. 300 ⁇ L, more preferably 20-300 ⁇ L at a concentration of 0.25-1 mM.
- the amount of the transition metal compound according to the present invention to be used is usually 5 ⁇ L to 1 mL at a concentration of 0.01 to 10 mmM for 25 ⁇ L of the sample, preferably. is 10 to 500 ⁇ L at a concentration of 0.05 to 5 mM, more preferably 20 to 300 ⁇ L at a concentration of 0.1 to 2 mM, still more preferably 20 to 300 ⁇ L at a concentration of 0.25 to 1 mM. be.
- the concentration of the transition metal compound with respect to the concentration of the luminescent substrate is The lower limit of the concentration of the transition metal compound in the solution is usually 0.0005 mM or more, preferably 0.005 mM or more, more preferably 0.05 mM or more, and still more preferably 0.1 mM with respect to the substrate concentration of 1 mM.
- the upper limit is usually 10 mM or less, preferably 5 mM or less, more preferably 2.5 mM or less, still more preferably 1 mM or less.
- the amount of oxidation catalyst used in the measurement method of the present invention may vary depending on the type of catalyst used and the mode of measurement. When measuring the amount of luminescence, it is usually 5 ⁇ L to 1 mL at a concentration of 0.001 to 1 ⁇ mol/L, preferably 10 to 500 ⁇ L at a concentration of 0.005 to 0.5 ⁇ mol/L, with respect to 25 ⁇ L of a sample. and more preferably 20 to 300 ⁇ L at a concentration of 0.01 to 0.1 ⁇ mol/L.
- the amount of peroxidase (POD) to be used is usually 5 ⁇ L to 1 mL at a concentration of 0.001 to 1 ⁇ mol/L with respect to 25 ⁇ L of the sample, preferably The concentration is 0.005-0.5 ⁇ mol/L and the volume is 10-500 ⁇ L, and the concentration is 0.01-0.1 ⁇ mol/L and the volume is more preferably 20-300 ⁇ L.
- the amount of oxidizing agent used in the measurement method of the present invention may vary depending on the type of oxidizing agent used and the mode of measurement, so it cannot be generalized.
- the concentration (w/v) of the hydrogen peroxide solution is usually 0.001 to 0.5% with a concentration of 0.001 to 0.5%, and the concentration is preferably 5 ⁇ L to 1 mL with respect to 25 ⁇ L of the sample.
- 0.005 to 0.25% concentration is 10 to 500 ⁇ L, more preferably 0.01 to 0.1% concentration is 20 to 300 ⁇ L.
- the amount of hydrogen peroxide to be used is usually 0.001 to 0.001 to 0.001 as the concentration (w/v) of hydrogen peroxide solution with respect to 25 ⁇ L of the sample.
- 5% concentration is 2.5 to 500 ⁇ L, preferably 0.005 to 0.25% concentration is 5 to 250 ⁇ L, more preferably 0.01 to 0.1% concentration is 10 to 150 ⁇ L.
- the amount of the sensitizer (enhancer) used in the measurement method of the present invention may vary depending on the type of sensitizer (enhancer) used and the mode of measurement, so it cannot be generalized.
- the agent (enhancer) is a thiazole derivative and the total luminescence amount is measured
- the concentration is usually 0.1 ⁇ M to 10 mM, and the concentration is usually 5 ⁇ L to 1 mL, preferably 1 ⁇ M to 2 mM, relative to 25 ⁇ L of the sample. 10 to 500 ⁇ L at a concentration of 10 ⁇ M to 1 mM, and more preferably 20 to 300 ⁇ L at a concentration of 10 ⁇ M to 1 mM.
- the amount of the thiazole derivative to be used is usually 5 ⁇ L to 1 mL at a concentration of 0.1 ⁇ M to 10 mM, preferably 1 ⁇ M to 2 mM, with respect to 25 ⁇ L of the sample. 10 to 500 ⁇ L at a concentration of 10 ⁇ M to 1 mM, and more preferably 20 to 300 ⁇ L at a concentration of 10 ⁇ M to 1 mM.
- surfactants and activators are added to the measurement system for the purpose of avoiding the influence of components other than the target substance contained in the sample, or for the purpose of increasing the detection sensitivity of the target substance.
- the amount of these additives to be added may be appropriately set within the range used in this field.
- the luminescence reaction of the luminescent substrate in the measurement method of the present invention may be carried out under conditions of usually pH 5-12, preferably pH 6-11, more preferably pH 6.5-10.5.
- Adjustment to such a pH can be carried out by adjusting the pH of a solution such as a solution (luminescent substrate solution).
- a solution such as a solution (luminescent substrate solution).
- the pH may be adjusted by using diluting water and/or buffer.
- examples of such a buffer solution include the same specific examples as those given for the composition of the present invention, and preferred specific examples are also the same.
- the concentration of the buffering agent contained in the above buffer solution is also the same as the range described above.
- the luminescent reaction of the luminescent substrate and subsequent measurement of the amount of luminescence in the measurement method of the present invention may be performed under temperature conditions of usually 10 to 60°C, preferably 15 to 50°C, more preferably 20 to 45°C.
- the time required for the luminescence reaction of the luminescent substrate and subsequent luminescence measurement in the measurement method of the present invention is usually 1 second to 20 minutes, preferably 5 seconds to 15 minutes, more preferably 10 seconds to 10 minutes.
- an antigen-antibody reaction is performed to form an enzyme-labeled immune complex, and the complex is subjected to the measurement method of the present invention.
- the antigen-antibody reaction may be performed under the same pH and temperature conditions as the luminescence reaction of the luminescence substrate in the above measurement method.
- the reaction time for the antigen-antibody reaction described above is usually 10 seconds to 120 minutes, preferably 30 seconds to 60 minutes, more preferably 1 to 30 minutes.
- the measurement method of the present invention can be applied to the measurement method and detection method using the above-described chemiluminescence reaction, for example, in the fields of clinical testing, biochemistry, and biology.
- a method for example, an immunocomplex is formed between an antibody or antigen labeled with a luminescent substrate or an oxidation catalyst or the like and the target substance in the sample, and the amount of luminescence of the chemiluminescent substance in the complex is measured.
- Luminescence immunoassay (CLIA), chemiluminescence enzyme immunoassay (CELIA), electrochemiluminescence immunoassay (ECLEIA) and the like.
- the amount of luminescence may be measured directly or indirectly by measuring the amount of luminescence of the target substance, or by measuring the amount of luminescence of a substance that competes with the target substance (competitive substance).
- an antibody against a target substance labeled with an oxidation catalyst such as peroxidase (POD) is reacted with the target substance in the presence of the transition metal compound of the present invention.
- an oxidation catalyst such as peroxidase (POD)
- POD peroxidase
- a method for measuring a target substance characterized by measuring the amount of light emitted from the substance.
- the above-mentioned target substance is not particularly limited as long as it is possible to obtain an antibody or antigen against it by any method.
- All measurement target substances that are usually considered measurable by complement immunoassay such as drugs, steroids, peptides, hormones, hepatitis markers, cancer markers, antibodies, and serum proteins, can be mentioned.
- endocrine function-related substances such as thyroid stimulating hormone (TSH), parathyroid hormone (iPTH), growth hormone (GH), somatomedin C (IGF-1), luteinizing hormone (LH), follicle stimulating hormone hormone (FSH), prolactin (PRL), adrenocorticotropic hormone (ACTH), vasopressin, oxytocin, somatostatin, enkephalin, ⁇ -endorphin, thyroxine, triiodothyronine, thyroglobulin, antithyroglobulin antibody, anti-T3 antibody, anti-T4 antibody , anti-TSH antibody, calcitonin, catecholamines, dopamine, serotonin, aldosterone, renin, angiotensin, cortisol, deoxycortisol, cortisone, corticosterone, deoxycorticosterone, androsterone, progesterone, pregnenolone,
- Tumor-related substances include , CEA, ferritin, ⁇ 2-microglobulin, elastase, ⁇ -fetoprotein, nerve-specific enolase, prostate-specific antigen, CA19-9, etc.
- Drugs and vitamin-related substances include phenobarbital, phenytoin, carbamazepine, primidone, ethosuximide , valproic acid, acetazolamide, sultiam, glutethimide, clonazepam, nitrazepam, diazepam, pentobarbital, secobarbital, bupivacaine, mepivacaine, lidocaine, procainamide, quinidine, digoxin, dikitoxin, theophylline, amitriptyline, imipramine, amikacin, gentamicin, tobramycin, cephalexin, sulfamethoxazole, methotrexate, cyclospor
- the above-mentioned sample may be derived from a subject animal, for example, whole blood, serum, plasma, urine, saliva, cerebrospinal fluid, tissue fluid, sweat, tears, amniotic fluid, bone marrow fluid, pleural fluid, ascitic fluid, joint fluid. , aqueous humor, and vitreous humor.
- TSH thyroid-stimulating hormone
- a sample, anti-thyroid stimulating hormone antibody (hereinafter sometimes abbreviated as anti-TSH antibody) is bound to a suitable automatic analyzer equipped with a mechanism for maintaining a constant atmosphere around the reaction vessel and/or the reaction vessel in the photometry room.
- a luminescent substrate solution) and a solution containing hydrogen peroxide are loaded, respectively.
- the analyzer is started, and the sample containing TSH is reacted with the solution containing anti-TSH antibody-bound magnetic particles to form an "anti-TSH antibody-bound magnetic particle-TSH” complex, followed by B/F separation. do.
- the solution containing the "anti-TSH antibody-bound magnetic particle-TSH” complex is added with the POD-labeled anti-TSH antibody-containing solution to react to give "anti-TSH antibody-bound magnetic particle-TSH-POD-labeled anti-TSH antibody".
- a complex is formed and B/F separation is performed.
- a luminescent substrate solution and a solution containing hydrogen peroxide are added to the magnetic particles subjected to B/F separation, and after mixing, the amount of luminescence derived from TSH contained in the sample may be measured.
- a sample a solution containing anti-TSH antibody-bound magnetic particles, Peroxidase (POD)-labeled anti-TSH antibody solution, solution containing luminol sodium salt, sodium orthovanadate (V) and 4-(4-hydroxyphenyl)thiazole as an enhancer (luminescent substrate solution), peroxide
- POD Peroxidase
- V sodium orthovanadate
- 4-(4-hydroxyphenyl)thiazole as an enhancer
- the analyzer is started, and the sample containing TSH, the solution containing the anti-TSH antibody-bound magnetic particles, and the solution containing the POD-labeled anti-TSH antibody are reacted to form "anti-TSH antibody-bound magnetic particles-TSH-POD-labeled Anti-TSH antibody' complex is formed and B/F separated.
- a luminescent substrate solution and a solution containing hydrogen peroxide may be added to magnetic particles subjected to B/F separation, and after mixing, the amount of luminescence derived from TSH contained in the sample may be measured.
- the magnetic particles used in the measurement method of the present invention are not particularly limited as long as they are magnetic particles used in this field. good.
- Antigen- or antibody-bound magnetic particles such as anti-TSH antibody-bound magnetic particles, may be produced using the above magnetic particles according to a method known per se.
- the sample and various reagents are reacted manually to cause a luminescence reaction. / and set in a spectrometer equipped with a mechanism for maintaining a constant atmosphere around the reaction vessel in the photometry chamber, and measure the amount of luminescence originating from the target substance contained in the sample.
- the coexistence of the transition metal compound of the present invention with the luminescent substrate improves the stability of the solution containing the luminescent substrate in a solution state, and increases the luminescence intensity of the luminescent substrate. Since the decrease (decrease in measurement sensitivity) can be suppressed and the luminescence amount of the luminescent substrate is unlikely to be adversely affected, the luminescence amount derived from the target substance can be measured with high sensitivity and accuracy.
- kits for luminescence measurement include, for example, a reagent containing the transition metal compound according to the present invention, a reagent containing a luminescent substrate, a reagent containing an oxidizing agent, and a reagent containing an oxidation catalyst. and a kit containing a reagent containing a transition metal compound and a luminescent substrate according to the present invention, a reagent containing an oxidizing agent, and a reagent containing an oxidation catalyst.
- the contents of the luminescent substrate, the transition metal compound according to the present invention, the oxidizing agent, and the oxidation catalyst contained in the kit for luminescence measurement described above are as follows:
- the final concentration and concentration ratio of each component of the agent and the oxidation catalyst may be contained within the ranges described above.
- the kit for luminescence measurement described above contains additives used in this field, such as sensitizers, activators, preservatives, stabilizers, preservatives, and surfactants. agents may be included. The content of these additives may be appropriately set within the range used in this field.
- kits for luminescence measurement containing such additives include the following.
- a luminescence measurement kit containing a reagent containing a transition metal compound according to the present invention, a reagent containing a luminescent substrate, a reagent containing an oxidizing agent and a sensitizer (enhancer), and a reagent containing an oxidation catalyst.
- agents containing transition metal compounds of the present invention agents containing luminescent substrates, agents containing oxidizing agents, agents containing oxidation catalysts, and agents containing sensitizers (enhancers), Luminescence measurement kit.
- a luminescence measurement kit containing a reagent containing a transition metal compound according to the present invention, a reagent containing a luminescent substrate, a reagent containing an oxidizing agent, a reagent containing an oxidation catalyst, and a reagent containing magnetic particles .
- kits for measuring luminescence comprising: (vii) a reagent containing a transition metal compound according to the present invention, a reagent containing a luminescent substrate and a sensitizer (enhancer), a reagent containing an oxidizing agent, a reagent containing an oxidation catalyst, and a reagent containing magnetic particles
- a kit for measuring luminescence comprising: (viii) a reagent containing a transition metal compound according to the present invention, a reagent containing a luminescent substrate, a reagent containing an oxidizing agent and a sensitizer (enhancer), a reagent containing an oxidation
- a kit for luminescence measurement containing reagents containing reagents.
- a luminescence measurement kit comprising a reagent containing a transition metal compound and a luminescent substrate according to the present invention, a reagent containing an oxidizing agent and a sensitizer (enhancer), and a reagent containing an oxidation catalyst.
- a luminescence measurement kit containing a reagent containing a transition metal compound and a luminescent substrate according to the present invention, a reagent containing an oxidizing agent, a reagent containing an oxidation catalyst, and a reagent containing a sensitizer (enhancer); .
- a luminescence measurement kit comprising a reagent containing a transition metal compound and a luminescent substrate according to the present invention, a reagent containing an oxidizing agent, a reagent containing an oxidation catalyst, and a reagent containing magnetic particles.
- luminescence including reagents containing transition metal compounds of the present invention, luminescent substrates and sensitizers (enhancers), reagents containing oxidizing agents, reagents containing oxidation catalysts, and reagents containing magnetic particles; Measurement kit.
- luminescence including reagents containing transition metal compounds and luminescent substrates according to the present invention, reagents containing oxidizing agents and sensitizers (enhancers), reagents containing oxidation catalysts, and reagents containing magnetic particles Measurement kit.
- a reagent containing a transition metal compound and a luminescent substrate according to the present invention a reagent containing an oxidizing agent, a reagent containing an oxidation catalyst, a reagent containing a sensitizer (enhancer), and a reagent containing magnetic particles
- a kit for measuring luminescence comprising:
- each reagent in the kit for luminescence measurement described above may be a solution state, a frozen state, or a freeze-dried state.
- test solution for luminescence measurement examples include the following.
- a reagent solution for measuring luminescence comprising a luminescent substrate solution containing the transition metal compound and the luminescent substrate according to the present invention, a solution containing an oxidizing agent, and a solution containing an oxidation catalyst.
- the contents of the luminescent substrate, the transition metal compound according to the present invention, the oxidizing agent, and the oxidation catalyst contained in the reagent solution for luminescence measurement described above are as follows:
- the final concentration and concentration ratio of each component of the agent and the oxidation catalyst may be contained within the ranges described above.
- the reagent solution for luminescence measurement described above contains additives used in this field, such as sensitizers, activators, preservatives, stabilizers, preservatives, and surfactants. agents may be included. The content of these additives may be appropriately set within the range used in this field.
- the present invention also discloses stabilizers for luminescent substrates comprising transition metal compounds selected from vanadium compounds, niobium compounds or tantalum compounds.
- the stabilizing method of the present invention described above can be performed by using a stabilizer for a luminescent substrate. Specifically, a luminescent substrate stabilizer is added to a reagent containing a luminescent substrate, a luminescent substrate or a reagent containing a luminescent substrate is added to a luminescent substrate stabilizer, a reagent containing a luminescent substrate and luminescence
- the transition metal compound can coexist with the luminescent substrate by means of adding the stabilizer for the substrate to a solution such as water or an appropriate buffer solution.
- the luminescent substrate stabilizer may be a reagent that is the above transition metal compound alone, or a reagent containing the above transition metal compound and other compounds. Other compounds include additives used in the art, such as enhancers, activators, preservatives, stabilizers, preservatives, surfactants, and the like.
- the luminescent substrate stabilizer is preferably provided in a form that does not itself contain a luminescent substrate.
- stabilizers for luminescent substrates include the "reagent containing the transition metal compound according to the present invention” and the “reagent containing the transition metal compound according to the present invention and a sensitizer (enhancer)" in the kit described above. be done.
- Luminescent Substrate Solution (1-A Solution) Luminol sodium salt (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) 398 mg, 4-(4-hydroxyphenyl)thiazole at a concentration of 35.4 mg/mL
- DMSO dimethyl sulfoxide
- (1-A' solution) A luminol solution was prepared in the same manner as (1-A solution) except that sodium orthovanadate (V) was not added. The above luminol solution was stored at 11° C. or 37° C. and used for measurement after 7 days of storage.
- Magnetic silica particles (manufacturing example described in WO 2012/173002) 1) was reacted with 3-aminopropyltriethoxysilane (manufactured by Shin-Etsu Chemical Co., Ltd.) and succinic anhydride (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), and then magnetized silica with a neodymium magnet. Magnetic silica particles having carboxyl groups were obtained by collecting the particles and removing the supernatant.
- N-hydroxysuccinimide manufactured by Fuji Film Wako Pure Chemical Industries, Ltd.
- WSC 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
- MES 2-(N-morpholino)ethanesulfonic acid
- a reagent containing bound magnetic particles was prepared and stored in a refrigerator (2-10°C) until use for measurement.
- a standard TSH solution with a TSH concentration of 0.05 ⁇ IU/mL or 0.2 ⁇ IU/mL prepared with 50 mM 3-(N-morpholino)propanesulfonic acid (MOPS) buffer (pH 7.5) was added to the test tube.
- the mixture was added, mixed, and allowed to react at 37° C. for 3 minutes to form an “anti-TSH antibody-bound magnetic particle-TSH” complex.
- the magnetic particles were collected with a neodymium magnet, the supernatant was removed, 100 ⁇ L of physiological saline was added, the magnetic particles were dispersed, and after the magnetic collection, the washing operation of removing the supernatant was performed three times.
- an enzyme-labeled reagent peroxidase (POD)-labeled anti-TSH antibody solution
- POD peroxidase
- 50 ⁇ L of an enzyme-labeled reagent is added to the test tube and reacted at 37° C. for 3 minutes to form an “anti-TSH antibody-bound magnetic particle-TSH-POD-labeled anti-TSH antibody” complex.
- the magnetic particles are collected with a neodymium magnet, the liquid is removed by suction with an aspirator, and then 100 ⁇ L of physiological saline is added to disperse the magnetic particles and after collecting the magnetic flux, the liquid is removed by suction with an aspirator. times.
- Example 1 Preparation of luminescent substrate solution (luminol solution) (1-B solution) Example 1 except that sodium orthovanadate (V) was not added and borate buffer was used instead of EPPS buffer (1-A solution), a luminol solution (luminol concentration: 2 mM, boric acid concentration: 200 mM, pH 8.55) was prepared. The above luminol solution was stored at 11° C. or 37° C. and used for measurement after 7 days of storage.
- Example 2- Preparation of luminescent substrate solution (luminol solution) (1-C solution) The same procedure as in Example 1 (1-A solution) except that boric acid was used instead of sodium orthovanadate (V) A luminol solution (luminol concentration: 2 mM, boric acid concentration (w/v): 0.1%, pH 8.55) was prepared. The above luminol solution was stored at 11° C. or 37° C. and used for measurement after 7 days of storage.
- the amount of luminescence was measured in the same manner for the luminescent substrate solution (1-C' solution) containing no boric acid, and the amount of luminescence after storage at 37°C for 7 days with respect to the amount of luminescence at 11°C (ratio of luminescence at 11°C) was calculated. Calculated. Based on the calculation results, the effect of stabilizing the luminol solution with or without boric acid was evaluated. The results are shown in Table 1 together with the results of Example 1 and Comparative Example 1.
- the luminescent substrate solution obtained by adding sodium orthovanadate (V) (transition metal compound according to the present invention) to luminol (luminescent substrate) produced orthovanadate (V)
- V transition metal compound according to the present invention
- the decrease in the luminescence amount (decrease in measurement sensitivity) of the luminescent substrate solution after long-term storage can be suppressed compared to the luminescent substrate solution to which sodium is not added.
- orthovanadic acid (V) suppresses the decomposition and deterioration of luminol and stabilizes luminol, thereby suppressing the decrease in the amount of light emitted from the luminescent substrate (decrease in measurement sensitivity).
- Example 1 composition of the present invention
- V sodium orthovanadate
- Luminescent Substrate Solution (1-D Solution to 1-G Solution) Except for using the following additives instead of sodium orthovanadate (V), (1 A luminol solution was prepared in the same manner as in A solution). The above luminol solution was stored at 11° C. or 37° C. and used for measurement after 7 days of storage.
- 1-D solution sodium metavanadate (V) (concentration: 1 mM)
- E solution ammonium metavanadate (V) (concentration: 1 mM)
- F solution sodium sulfate (concentration: 1 mM)
- 1-G solution lithium chloride (concentration: 1 mM)
- the luminescence level of the luminescence substrate solution (1-X' solution) containing no additive was also measured in the same manner, and the luminescence level after storage at 37°C for 7 days with respect to the luminescence level at 11°C (ratio of the luminescence level at 11°C) was calculated. Calculated. Based on the calculation results, the effect of stabilizing the luminol solution with and without various additives was evaluated. The results are shown in Table 2 together with the results of Comparative Examples 1 and 2.
- luminous substrate solutions obtained by adding sodium metavanadate (V) or ammonium metavanadate (V) (transition metal compound according to the present invention) to luminol (luminescent substrate) was found to be able to suppress the decrease in the amount of luminescence (decrease in measurement sensitivity) of the luminescent substrate solution after long-term storage compared to the luminescent substrate solution without these additives.
- This result suggests that not only orthovanadic acid (V) of Example 1 but also various transition metal compounds according to the present invention can suppress the decrease in the luminescence amount of the luminescent substrate (decrease in measurement sensitivity).
- the luminescent substrate solutions of Examples 2 and 3 to which sodium metavanadate (V) and ammonium metavanadate (V) were added compositions of the present invention
- the luminescent substrate solution of Comparative Example 1 using boric acid as a buffer solution and the luminescent substrate solution of Comparative Example 2 using boric acid as an additive it is possible to have the same or more stabilizing effect of the luminescent substrate. all right.
- the amount of luminescence was measured in the same manner for the luminescence substrate solutions (1-H' solution to 1-J' solution) using various buffers that did not contain orthovanadic acid (V). The amount of luminescence (ratio of luminescence at 11°C) after storage at 11°C for 7 days was calculated. Based on the calculation results, the stabilizing effect of the luminol solution when using various buffers was evaluated. The results are shown in Table 3 together with the results of Comparative Examples 1 and 2.
- the luminescent substrate solution shows a decrease in the luminescence amount of the luminescent substrate solution after long-term storage (decrease in measurement sensitivity) compared to the luminescent substrate solution to which sodium orthovanadate (V) is not added. was found to be suppressed.
- the luminescent substrate solutions (compositions of the present invention) of Examples 4 to 6 to which sodium orthovanadate (V) was added had boric acid as a buffer solution. and the luminescent substrate solution of Comparative Example 2 using boric acid as an additive, the luminescent substrate stabilizing effect was found to be equal to or greater than that of the luminescent substrate solution.
- the luminescence level of the luminescence substrate solution (1-Y' solution) that does not contain orthovanadic acid (V) was measured in the same manner, and the luminescence level after storage at 37°C for 7 days compared to the luminescence level at 11°C (vs. luminescence at 11°C) ratio) was calculated. Based on the calculation results, the stabilizing effect of luminol solutions containing various concentrations of orthovanadic acid (V) was evaluated. The results are shown in Table 4 together with the results of Comparative Examples 1 and 2.
- luminol luminescent substrate contains sodium orthovanadate (V).
- the luminescent substrate solution (composition of the present invention) to which the (transition metal compound according to the present invention) has been added is more stable after long-term storage than the luminescent substrate solution to which sodium orthovanadate (V) is not added. It was found that the decrease in luminescence (decrease in measurement sensitivity) can be suppressed.
- the luminescent substrate solutions (compositions of the present invention) of Examples 7 to 9 to which sodium orthovanadate (V) was added had boric acid as a buffer solution.
- the luminescent substrate solution of Comparative Example 2 using boric acid as an additive the luminescent substrate stabilizing effect was found to be equal to or greater than that of the luminescent substrate solution.
- Example 10- Preparation of luminescence substrate solution (Luminol solution) A luminol solution was prepared. The above luminol solution was stored at 11° C. or 37° C. and used for measurement after 7 days of storage. 1-N solution: concentration 50 mM
- the luminescence level of the luminescence substrate solution (1-N' solution) that does not contain orthovanadic acid (V) was measured, and the luminescence level after storage at 37°C for 7 days compared to the luminescence level at 11°C (vs. 11°C luminescence ratio) was calculated. Based on the calculation results, the stabilizing effect of the luminol solution containing orthovanadic acid (V) was evaluated. The results are shown in Table 5 together with the results of Example 1 and Comparative Examples 1 and 2.
- luminol luminescence substrate
- the luminescent substrate solution (composition of the present invention) to which sodium orthovanadate (V) is added (the composition of the present invention) exhibits a decrease in the luminescence amount of the luminescent substrate solution after long-term storage (measurement decrease in sensitivity) can be suppressed.
- the luminescent substrate solution of Example 10 (composition of the present invention) to which sodium orthovanadate (V) was added was compared with boric acid as a buffer solution. Compared with the luminescent substrate solution of Example 1 and the luminescent substrate solution of Comparative Example 2 using boric acid as an additive, it was found that the luminescent substrate stabilization effect was equal to or greater than that of the luminescent substrate solution.
- Example 11 (1-O solution) 8-amino-5-chloro-7-phenylpyrido[3,4-d]pyridazine-1,4(2H, 3H)-dione (L-012) sodium salt (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.) 156 mg, 4-(4-hydroxyphenyl) thiazole (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.) at a concentration of 35.4 mg/mL ) in dimethyl sulfoxide (DMSO) (manufactured by FUJIFILM Wako Pure Chemical Industries, Ltd.) was charged into a 1000 mL volumetric flask.
- DMSO dimethyl sulfoxide
- Examples 12 and 13 (1-P solution to 1-Q solution) Same as (1-O solution) in Example 11, except that the concentration of sodium orthovanadate (V) was changed to the concentration shown below.
- the procedure prepared the L-012 solution. The above L-012 solution was stored at 11° C. or 37° C. and used for measurement after 7 days of storage.
- 1-P solution concentration 0.5 mM
- 1-Q solution concentration 2.5 mM
- the amount of light emitted from the substrate solution (solution 1-Z') was also measured in the same manner, and the amount of light emitted after storage at 37°C for 7 days with respect to the amount of light emitted at 11°C (ratio of the amount of light emitted at 11°C) was calculated. Based on this, the stabilizing effect of L-012 solutions containing various concentrations of orthovanadic acid (V) was evaluated. The results are shown in Table 6.
- the luminescent substrate solution obtained by adding sodium orthovanadate (V) (transition metal compound according to the present invention) to L-012 It was found that the (composition of the present invention) can suppress the decrease in the amount of luminescence (decrease in measurement sensitivity) of the luminescent substrate solution after long-term storage compared to the luminescent substrate solution to which sodium orthovanadate (V) is not added. rice field. Based on these results, orthovanadic acid (V) suppresses the decomposition and deterioration of not only luminol but also various luminescent substrates such as L-012.
- the luminescent substrate solution containing the transition metal compound according to the present invention (the composition of the present invention) can improve the stability of the luminescent substrate in solution. It was found that the decrease in the luminescence amount of the luminescence substrate (decrease in measurement sensitivity) due to the decomposition or deterioration of the luminescence substrate can be suppressed, and the target substance can be detected and measured with high accuracy.
- the composition and stabilization method of the present invention can improve the stability of the luminescent substrate by allowing the luminescent substrate to coexist with a transition metal compound selected from vanadium compounds, niobium compounds and tantalum compounds. As a result, it is possible to suppress the decrease in the luminescence amount of the luminescent substrate (decrease in measurement sensitivity) due to the decomposition or deterioration of the luminescent substrate. , the target substance in the living body can be measured with high sensitivity and accuracy.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
(1)バナジウム化合物、ニオブ化合物またはタンタル化合物から選ばれる遷移金属化合物と発光基質とを含有する組成物(以下、本発明の組成物と略記する場合がある)。
バナジウム化合物、ニオブ化合物またはタンタル化合物から選ばれる遷移金属化合物を含む、発光基質用安定化剤。
また、本明細書において、「mM」は「mmol/l」と同義である。
本発明の組成物は、バナジウム化合物、ニオブ化合物またはタンタル化合物から選ばれる遷移金属化合物(以下、本発明にかかる遷移金属化合物と略記する場合がある。)と発光基質とを含有するものである。本発明の組成物の保管時や使用時(測定時)において、遷移金属化合物の作用により、発光基質の分解や劣化が抑えられる。例えば、化学発光測定において、本発明の組成物を用いれば、生体中の目的物質を高感度で精度よく測定することができる。
本発明の安定化方法は、発光基質に、バナジウム化合物、ニオブ化合物またはタンタル化合物から選ばれる遷移金属化合物を共存させる方法である。
本発明の測定方法は、本発明にかかる遷移金属化合物の共存下、発光基質と酸化剤と酸化触媒とを反応させて、発光量を測定する方法である。すなわち、本発明の測定方法は、発光基質の発光反応と、それにより生じた化学発光物質の発光量を測定する方法である。本発明の測定方法を用いれば、試料中に含まれる目的物質の有無や量を検出することができる。
本発明の測定方法に使用される発光基質液、各種試薬、溶液等は、キットの形態として供してもよい。このような発光測定用キットの具体例としては、例えば、本発明にかかる遷移金属化合物を含有する試剤と、発光基質を含有する試剤と、酸化剤を含有する試剤と、酸化触媒を含有する試剤とを含むキットや、本発明にかかる遷移金属化合物と発光基質とを含有する試剤と、酸化剤を含有する試剤と、酸化触媒を含有する試剤とを含むキット等が挙げられる。
(i)本発明にかかる遷移金属化合物および増感剤(エンハンサー)を含有する試剤、発光基質を含有する試剤、酸化剤を含有する試剤、ならびに酸化触媒を含有する試剤を含む、発光測定用キット。
(ii)本発明にかかる遷移金属化合物を含有する試剤、発光基質および増感剤(エンハンサー)を含有する試剤、酸化剤を含有する試剤、ならびに酸化触媒を含有する試剤を含む、発光測定用キット。
(iii)本発明にかかる遷移金属化合物を含有する試剤、発光基質を含有する試剤、酸化剤および増感剤(エンハンサー)を含有する試剤、ならびに酸化触媒を含有する試剤を含む、発光測定用キット。
(iv)本発明にかかる遷移金属化合物を含有する試剤、発光基質を含有する試剤、酸化剤を含有する試剤、酸化触媒を含有する試剤、ならびに増感剤(エンハンサー)を含有する試剤を含む、発光測定用キット。
(v)本発明にかかる遷移金属化合物を含有する試剤、発光基質を含有する試剤、酸化剤を含有する試剤、酸化触媒を含有する試剤、ならびに磁性粒子を含有する試剤を含む、発光測定用キット。
(vi)本発明にかかる遷移金属化合物および増感剤(エンハンサー)を含有する試剤、発光基質を含有する試剤、酸化剤を含有する試剤、酸化触媒を含有する試剤、ならびに磁性粒子を含有する試剤を含む、発光測定用キット。
(vii)本発明にかかる遷移金属化合物を含有する試剤、発光基質および増感剤(エンハンサー)を含有する試剤、酸化剤を含有する試剤、酸化触媒を含有する試剤、ならびに磁性粒子を含有する試剤を含む、発光測定用キット。
(viii)本発明にかかる遷移金属化合物を含有する試剤、発光基質を含有する試剤、酸化剤および増感剤(エンハンサー)を含有する試剤、酸化触媒を含有する試剤、ならびに磁性粒子を含有する試剤を含む、発光測定用キット。
(ix)本発明にかかる遷移金属化合物を含有する試剤、発光基質を含有する試剤、酸化剤を含有する試剤、酸化触媒を含有する試剤、増感剤を含有する試剤、ならびに磁性粒子を含有する試剤を含む、発光測定用キット。
(x)本発明にかかる遷移金属化合物、発光基質および増感剤(エンハンサー)を含有する試剤、酸化剤を含有する試剤、ならびに酸化触媒を含有する試剤を含む、発光測定用キット。
(xi)本発明にかかる遷移金属化合物および発光基質を含有する試剤、酸化剤および増感剤(エンハンサー)を含有する試剤、ならびに酸化触媒を含有する試剤を含む、発光測定用キット。
(xii)本発明にかかる遷移金属化合物および発光基質を含有する試剤、酸化剤を含有する試剤、酸化触媒を含有する試剤、ならびに増感剤(エンハンサー)を含有する試剤を含む、発光測定用キット。
(xiii)本発明にかかる遷移金属化合物および発光基質を含有する試剤、酸化剤を含有する試剤、酸化触媒を含有する試剤、ならびに磁性粒子を含有する試剤を含む、発光測定用キット。
(xiv)本発明にかかる遷移金属化合物、発光基質および増感剤(エンハンサー)を含有する試剤、酸化剤を含有する試剤、酸化触媒を含有する試剤、ならびに磁性粒子を含有する試剤を含む、発光測定用キット。
(xv)本発明にかかる遷移金属化合物および発光基質を含有する試剤、酸化剤および増感剤(エンハンサー)を含有する試剤、酸化触媒を含有する試剤、ならびに磁性粒子を含有する試剤を含む、発光測定用キット。
(xvi)本発明にかかる遷移金属化合物および発光基質を含有する試剤、酸化剤を含有する試剤、酸化触媒を含有する試剤、増感剤(エンハンサー)を含有する試剤、ならびに磁性粒子を含有する試剤を含む、発光測定用キット。
(I)本発明にかかる遷移金属化合物および発光基質を含有する発光基質液、酸化剤を含有する溶液、ならびに酸化触媒を含有する溶液を含む、発光測定用試液。
本発明はバナジウム化合物、ニオブ化合物またはタンタル化合物から選ばれる遷移金属化合物を含む、発光基質用安定化剤についても開示する。
発光基質用安定化剤を用いることにより、上述の本発明の安定化方法を行うことができる。
具体的には、発光基質を含有する試剤に発光基質用安定化剤を添加する、発光基質用安定化剤に発光基質又は発光基質を含有する試剤を添加する、発光基質を含有する試剤と発光基質用安定化剤とを水や適当な緩衝液等の溶解液に添加する、等の手段により、発光基質に遷移金属化合物を共存させることができる。
またこの共存下で発光量を測定することにより、本発明の測定方法を実施することができる。
発光基質用安定化剤は上記遷移金属化合物単体である試剤であってもよいし、上記遷移金属化合物及び他の化合物を含有する試剤であってもよい。
他の化合物としては、増感剤(エンハンサー)、賦活化剤、保存剤、安定化剤、防腐剤、界面活性剤等の、この分野において使用される添加剤が挙げられる。
発光基質用安定化剤は、それ自体が発光基質を含有しない形態で提供されることが好ましい。
発光基質用安定化剤としては、上述のキットにおける「本発明にかかる遷移金属化合物を含有する試剤」、「本発明にかかる遷移金属化合物および増感剤(エンハンサー)を含有する試剤」等が挙げられる。
ペルオキシダーゼ(POD)を用いた甲状腺刺激ホルモンの測定系において、試薬の調製、ならびに本発明に係る遷移金属化合物を用いた甲状腺刺激ホルモンの測定方法および評価方法を以下に示す。
(1)発光基質液(ルミノール溶液)の調製
(1-A液)ルミノールナトリウム塩(富士フイルム和光純薬(株)製)398mg、濃度35.4mg/mLの4-(4-ヒドロキシフェニル)チアゾール(富士フイルム和光純薬(株)製)のジメチルスルホキシド(DMSO)(富士フイルム和光純薬(株)製)溶液1mL、および塩化ナトリウム8.77gを1000mLメスフラスコに仕込んだ。次いで、オルトバナジン酸(V)ナトリウム(Santa Cruz Biotechnology社製)183.9mgを添加した後、3-[4-(2-ヒドロキシエチル)-1-ピペラジニル]プロパンスルホン酸(EPPS)緩衝液((株)同仁化学研究所製)を終濃度が150mMになるように添加し、5Nの水酸化ナトリウム水溶液でpH8.55に調整し、25℃で均一に混合してルミノール溶液1000mLを調製した(ルミノール濃度:2mM、オルトバナジン酸(V)濃度:1mM、pH8.55)。上記ルミノール溶液を11℃または37℃で保存し、保存後7日後のものを測定に使用した。
磁性シリカ粒子(国際公開第2012/173002号に記載の製造例1に準じて作製)に、3-アミノプロピルトリエトキシシラン(信越化学工業(株)製)および無水コハク酸(富士フイルム和光純薬(株)製)を反応させた後、ネオジウム磁石で磁性シリカ粒子を集磁し、上清を除去することで、カルボキシル基を有する磁性シリカ粒子を得た。次に、上記磁性シリカ粒子に、N-ヒドロキシコハク酸イミド(富士フイルム和光純薬(株)製)および塩酸1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド(WSC)((株)同仁化学研究所製)を用いて、抗TSH抗体(マウスモノクローナル抗体)を26℃で12~16時間反応させ、次いで、ブロッキング液{0.5%ブロックエース(雪印乳業(株)製)を加え、26℃で12~16時間反応させることにより、抗TSH抗体(マウスモノクローナル抗体)結合磁性粒子を作製した。これを、50mMの2-(N-モルホリノ)エタンスルホン酸(MES)緩衝液(pH5.5)で、抗TSH抗体結合磁性粒子濃度として1.0mg/mLの濃度となるように希釈し、抗体結合磁性粒子を含有する試薬(抗TSH抗体(マウスモノクローナル抗体)結合磁性粒子試薬)を調製し、測定に用いるまで冷蔵(2~10℃)で保存した。
50mMの2-(N-モルホリノ)エタンスルホン酸(MES)緩衝液(pH6.0)を調製し、免疫反応用緩衝液を得た。測定に用いるまで冷蔵(2~10℃)で保存した。
抗TSH抗体(マウスモノクローナル抗体)、西洋ワサビ由来PODを用い、文献(S. YOSHITAKE, M. IMAGAWA, E. ISHIKAWA, H. OGAWA; J Biochem (1982) Vol. 92, (5): 1413-1424)に記載の方法に準じて、POD標識抗TSH抗体(マウスモノクローナル抗体)を調製した。これを、50mMの2-(N-モルホリノ)エタンスルホン酸(MES)緩衝液(pH6.5)で、POD標識抗TSH抗体濃度として0.02μmol/Lの濃度となるように希釈し、酵素標識試薬(POD標識抗TSH抗体(マウスモノクローナル抗体)溶液)を調製し、測定に用いるまで冷蔵(2~10℃)で保存した。
過酸化水素水(富士フイルム和光純薬(株)製、試薬特級、濃度30重量%)336μLを1000mLメスフラスコに仕込んだ。次いで、蒸留水を用いて溶液の容量を1000mLにメスアップし、25℃で均一に混合して過酸化水素水溶液を調製した(過酸化水素濃度(w/v):0.02%)。測定に用いるまで冷蔵(2~10℃)で保存した。
(1)~(5)で得られた各試薬および溶液を用いて、以下に示す方法により、発光基質液(1-A液および1-A’)に基づいて発光量(平均値)を測定し、オルトバナジン酸(V)による発光基質の安定化効果を評価した。
抗体結合磁性粒子を含有する試薬(抗甲状腺刺激ホルモン抗体(抗TSH抗体)(マウスモノクローナル抗体)結合磁性粒子試薬)50μLをネオジウム磁石で抗体結合磁性粒子を集磁し、上清を除去した後、免疫反応用緩衝液50μLを添加した。次いで、50mMの3-(N-モルホリノ)プロパンスルホン酸(MOPS)緩衝液(pH7.5)で調製したTSH濃度が0.05μIU/mLまたは0.2μIU/mLの標準TSH溶液25μLを試験管に加えて混合し、37℃で3分間反応させて、「抗TSH抗体結合磁性粒子-TSH」複合体を形成させた。反応後、ネオジウム磁石で磁性粒子を集磁し、上清を除去した後、生理食塩水100μLを加え、磁性粒子を分散させて集磁後、上清を除去する洗浄操作を3回行った。
次いで、酵素標識試薬(ペルオキシダーゼ(POD)標識抗TSH抗体溶液)50μLを試験管に加え、37℃で3分間反応させて、「抗TSH抗体結合磁性粒子-TSH-POD標識抗TSH抗体」複合体を形成させた。反応後、ネオジウム磁石で磁性粒子を集磁し、液体をアスピレーターで吸引除去した後、生理食塩水100μLを加え、磁性粒子を分散させて集磁後、アスピレーターで液体を吸引除去する洗浄操作を3回行った。
次いで、発光基質液(1-A液または1-A’液)100μLと、過酸化水素水溶液100μLとを同時に加え、発光量を測定した。なお、これらの反応および発光量の測定は、全自動化学発光酵素免疫測定装置Accuraseed(登録商標)(富士フイルム和光純薬(株))を用いて行った。
(1)発光基質液(ルミノール溶液)の調製
(1-B液)オルトバナジン酸(V)ナトリウムを添加せずに、EPPS緩衝液の代わりにホウ酸緩衝液を用いた以外は、実施例1の(1-A液)と同様の操作により、ルミノール溶液(ルミノール濃度:2mM、ホウ酸濃度:200mM、pH8.55)を調製した。上記ルミノール溶液を11℃または37℃で保存し、保存後7日後のものを測定に使用した。
(1)で得られたルミノール溶液、ならびに実施例1の(2)~(5)で得られた各試薬および溶液を用いて、実施例1の(6)と同様の方法により、発光基質液(1-B液)を11℃下で保存した場合の発光量と37℃下で7日間保存後の発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。その結果を、実施例1の結果と合わせて表1に示す。
(1)発光基質液(ルミノール溶液)の調製
(1-C液)オルトバナジン酸(V)ナトリウムの代わりにホウ酸を用いた以外は、実施例1の(1-A液)と同様の操作により、ルミノール溶液(ルミノール濃度:2mM、ホウ酸濃度(w/v):0.1%、pH8.55)を調製した。上記ルミノール溶液を11℃または37℃で保存し、保存後7日後のものを測定に使用した。
(1)で得られた各ルミノール溶液、ならびに実施例1の(2)~(5)で得られた各試薬および溶液を用いて、実施例1の(6)と同様の方法により、添加剤としてホウ酸を含有する発光基質液(1-C液)を11℃下で保存した場合の発光量と37℃下で7日間保存後の発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。ホウ酸を含有しない発光基質液(1-C’液)についても同様に発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。その算出結果を基に、ホウ酸の有無によるルミノール溶液の安定化効果を評価した。その結果を、実施例1および比較例1の結果と合わせて表1に示す。
(1)発光基質液(ルミノール溶液)の調製
(1-D液~1-G液)オルトバナジン酸(V)ナトリウムの代わりに以下に示す添加剤を用いた以外は、実施例1の(1-A液)と同様の操作により、ルミノール溶液を調製した。上記ルミノール溶液を11℃または37℃で保存し、保存後7日後のものを測定に使用した。
1-D液:メタバナジン酸(V)ナトリウム(濃度:1mM)
1-E液:メタバナジン酸(V)アンモニウム(濃度:1mM)
1-F液:硫酸ナトリウム(濃度:1mM)
1-G液:塩化リチウム(濃度:1mM)
(1)で得られた各ルミノール溶液、ならびに実施例1の(2)~(5)で得られた各試薬および溶液を用いて、実施例1の(6)と同様の方法により、各種添加剤を含有する発光基質液(1-D液~1-G液)を11℃下で保存した場合の発光量と37℃下で7日間保存後の発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。添加剤を含有しない発光基質液(1-X’液)についても同様に発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。その算出結果を基に、各種添加剤の有無によるルミノール溶液の安定化効果を評価した。その結果を、比較例1~2の結果と合わせて表2に示す。
(1)発光基質液(ルミノール溶液)の調製
(1-H液~1-J液)EPPS緩衝液の代わりに以下に示す緩衝液を用いた以外は、実施例1の(1-A液)と同様の操作により、ルミノール溶液を調製した。上記ルミノール溶液を11℃または37℃で保存し、保存後7日後のものを測定に使用した。
1-H液:ピペラジン-1,4-ビス(2-ヒドロキシ-3-プロパンスルホン酸)(POPSO)緩衝液(濃度:150mM)
1-I液:N-シクロヘキシル-2-アミノエタンスルホン酸(CHES)緩衝液(濃度:150mM)
1-J液:ジエタノールアミン緩衝液(濃度:150mM)
(1)で得られた各ルミノール溶液、ならびに実施例1の(2)~(5)で得られた各試薬および溶液を用いて、実施例1の(6)と同様の方法により、オルトバナジン酸(V)を含有し、各種緩衝液を用いた発光基質液(1-H液~1-J液)を11℃下で保存した場合の発光量と37℃下で7日間保存後の発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。オルトバナジン酸(V)を含有しない、各種緩衝液を用いた発光基質液(1-H’液~1-J’液)についても同様に発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。その算出結果を基に、各種緩衝液を用いた場合のルミノール溶液の安定化効果を評価した。その結果を、比較例1~2の結果と合わせて表3に示す。
(1)発光基質液(ルミノール溶液)の調製
(1-K液~1-M液)オルトバナジン酸(V)ナトリウムの濃度を以下に示す濃度に変更した以外は、実施例1の(1-A液)と同様の操作により、ルミノール溶液を調製した。上記ルミノール溶液を11℃または37℃で保存し、保存後7日後のものを測定に使用した。
1-K液:濃度0.5mM
1-L液:濃度1mM
1-M液:濃度2.5mM
(1)で得られた各ルミノール溶液、ならびに実施例1の(2)~(5)で得られた各試薬および溶液を用いて、実施例1の(6)と同様の方法により、オルトバナジン酸(V)の濃度を種々の濃度に変更した発光基質液(1-K液~1-M液)を11℃下で保存した場合の発光量と37℃下で7日間保存後の発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。オルトバナジン酸(V)を含有しない発光基質液(1-Y’液)についても同様に発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。その算出結果を基に、種々の濃度のオルトバナジン酸(V)を含有した場合のルミノール溶液の安定化効果を評価した。その結果を、比較例1~2の結果と合わせて表4に示す。
(1)発光基質液(ルミノール溶液)の調製
(1-N液)EPPS緩衝液の濃度を以下に示す濃度に変更した以外は、実施例1の(1-A液)と同様の操作により、ルミノール溶液を調製した。上記ルミノール溶液を11℃または37℃で保存し、保存後7日後のものを測定に使用した。
1-N液:濃度50mM
(1)で得られた各ルミノール溶液、ならびに実施例1の(2)~(5)で得られた各試薬および溶液を用いて、実施例1の(6)と同様の方法により、EPPS緩衝液の濃度が50mMの発光基質液(1-N液)を11℃下で保存した場合の発光量と37℃下で7日間保存後の発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。オルトバナジン酸(V)を含有しない発光基質液(1-N’液)についても同様に発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。その算出結果を基に、オルトバナジン酸(V)を含有した場合のルミノール溶液の安定化効果を評価した。その結果を、実施例1および比較例1~2の結果と合わせて表5に示す。
(1)発光基質液(L-012溶液)の調製
実施例11:(1-O液)8-アミノ-5-クロロ-7-フェニルピリド[3,4-d]ピリダジン-1,4(2H,3H)-ジオン(L-012)ナトリウム塩(富士フイルム和光純薬(株)製)156mg、濃度35.4mg/mLの4-(4-ヒドロキシフェニル)チアゾール(富士フイルム和光純薬(株)製)のジメチルスルホキシド(DMSO)(富士フイルム和光純薬(株)製)溶液1mLを1000mLメスフラスコに仕込んだ。次いで、オルトバナジン酸(V)ナトリウム(Santa Cruz Biotechnology社製)183.9mgを添加し、EPPS緩衝液((株)同仁化学研究所製)を終濃度が50mMになるように添加し、5Nの水酸化ナトリウム水溶液でpH8.00に調整し、25℃で均一に混合してL-012溶液1000mLを調製した(L-012濃度:0.5mM、オルトバナジン酸(V)濃度:1mM、pH8.00)。上記L-012溶液を11℃または37℃で保存し、保存後7日後のものを測定に使用した。
1-P液:濃度0.5mM
1-Q液:濃度2.5mM
(1で得られた各L-012溶液、ならびに実施例1の(2)~(5)で得られた各試薬および溶液を用いて、実施例1の(6)と同様の方法により、オルトバナジン酸(V)の濃度を種々の濃度に変更した発光基質液(1-O液~1-Q液)を11℃下で保存した場合の発光量と37℃下で7日間保存後の発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。オルトバナジン酸(V)を含有しない発光基質液(1-Z’液)についても同様に発光量を測定し、11℃下の発光量に対する37℃7日間保存後の発光量(対11℃発光量比)を算出した。その算出結果を基に、種々の濃度のオルトバナジン酸(V)を含有した場合のL-012溶液の安定化効果を評価した。その結果を表6に示す。
Claims (16)
- バナジウム化合物、ニオブ化合物またはタンタル化合物から選ばれる遷移金属化合物と発光基質とを含有する組成物。
- 前記遷移金属化合物が、バナジウム化合物である、請求項1に記載の組成物。
- 前記一般式(1)で表される化合物と発光基質とを含有する、請求項3に記載の組成物。
- 前記一般式(1)におけるZ1が、バナジウム原子である、請求項4に記載の組成物。
- 前記一般式(1)で表される化合物が、オルトバナジン酸、オルトバナジン酸のアルカリ金属塩、オルトバナジン酸のアンモニウム塩、メタバナジン酸、メタバナジン酸のアルカリ金属塩またはメタバナジン酸のアンモニウム塩である、請求項4に記載の組成物。
- 前記発光基質が、ルミノール類または化学的に許容される塩、あるいは8-アミノ-5-クロロ-7-フェニルピリド[3,4-d]ピリダジン-1,4(2H,3H)-ジオンまたは化学的に許容される塩である、請求項1に記載の組成物。
- 前記遷移金属化合物が、発光基質を安定化させるためのものである、請求項1に記載の組成物。
- 組成物中における前記遷移金属化合物の濃度が、0.01~10mMである、請求項1に記載の組成物。
- 組成物のpHが、5~12である、請求項1に記載の組成物。
- 発光基質に、バナジウム化合物、ニオブ化合物またはタンタル化合物から選ばれる遷移金属化合物を共存させる、発光基質の安定化方法。
- 前記発光基質を含む溶液に、前記遷移金属化合物を添加して共存させる、請求項11に記載の安定化方法。
- バナジウム化合物、ニオブ化合物またはタンタル化合物から選ばれる遷移金属化合物の共存下、発光基質と酸化剤と酸化触媒とを反応させて、発光量を測定する方法。
- バナジウム化合物、ニオブ化合物またはタンタル化合物から選ばれる遷移金属化合物を含む、発光基質用安定化剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22788211.5A EP4325210A4 (en) | 2021-04-16 | 2022-04-14 | COMPOSITION, STABILIZATION METHOD, METHOD FOR MEASURING LUMINESCENCE AMOUNT, AND STABILIZER FOR LUMINESCENT SUBSTRATE |
JP2023514683A JPWO2022220288A1 (ja) | 2021-04-16 | 2022-04-14 | |
US18/485,914 US20240043742A1 (en) | 2021-04-16 | 2023-10-12 | Composition, stabilization method, method for measuring amount of luminescence, and stabilizer for luminescent substrate |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021069924 | 2021-04-16 | ||
JP2021-069924 | 2021-04-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/485,914 Continuation US20240043742A1 (en) | 2021-04-16 | 2023-10-12 | Composition, stabilization method, method for measuring amount of luminescence, and stabilizer for luminescent substrate |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022220288A1 true WO2022220288A1 (ja) | 2022-10-20 |
Family
ID=83640759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/017860 WO2022220288A1 (ja) | 2021-04-16 | 2022-04-14 | 組成物、安定化方法、および、発光量を測定する方法、ならびに、発光基質用安定化剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240043742A1 (ja) |
EP (1) | EP4325210A4 (ja) |
JP (1) | JPWO2022220288A1 (ja) |
TW (1) | TW202307174A (ja) |
WO (1) | WO2022220288A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5401640A (en) * | 1992-03-30 | 1995-03-28 | Trustees Of Dartmouth College | Method for enhancing detection of superoxide anion |
JP2008185580A (ja) * | 2006-12-22 | 2008-08-14 | Commiss Energ Atom | プラズモン効果による光学符号化装置およびこの装置を使用した認証方法 |
JP2008203088A (ja) | 2007-02-20 | 2008-09-04 | Aloka Co Ltd | 抗酸化能評価方法及び抗酸化能評価キット |
WO2012173002A1 (ja) | 2011-06-15 | 2012-12-20 | 三洋化成工業株式会社 | 磁性シリカ粒子を用いた測定方法及び該測定方法用試薬 |
WO2017069192A1 (ja) | 2015-10-21 | 2017-04-27 | 和光純薬工業株式会社 | 安定化剤および安定化方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1034768C (zh) * | 1993-01-05 | 1997-04-30 | 于德胜 | 一种测定水样中二氧化硅含量的方法 |
WO2015183931A1 (en) * | 2014-05-28 | 2015-12-03 | Li-Cor, Inc. | Stabilized chemiluminescent system |
-
2022
- 2022-04-14 JP JP2023514683A patent/JPWO2022220288A1/ja active Pending
- 2022-04-14 EP EP22788211.5A patent/EP4325210A4/en active Pending
- 2022-04-14 WO PCT/JP2022/017860 patent/WO2022220288A1/ja active Application Filing
- 2022-04-15 TW TW111114400A patent/TW202307174A/zh unknown
-
2023
- 2023-10-12 US US18/485,914 patent/US20240043742A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5401640A (en) * | 1992-03-30 | 1995-03-28 | Trustees Of Dartmouth College | Method for enhancing detection of superoxide anion |
JP2008185580A (ja) * | 2006-12-22 | 2008-08-14 | Commiss Energ Atom | プラズモン効果による光学符号化装置およびこの装置を使用した認証方法 |
JP2008203088A (ja) | 2007-02-20 | 2008-09-04 | Aloka Co Ltd | 抗酸化能評価方法及び抗酸化能評価キット |
WO2012173002A1 (ja) | 2011-06-15 | 2012-12-20 | 三洋化成工業株式会社 | 磁性シリカ粒子を用いた測定方法及び該測定方法用試薬 |
WO2017069192A1 (ja) | 2015-10-21 | 2017-04-27 | 和光純薬工業株式会社 | 安定化剤および安定化方法 |
Non-Patent Citations (3)
Title |
---|
S. YOSHITAKEM. IMAGAWAE. ISHIKAWAH. OGAWA, J BIOCHEM, vol. 92, no. 5, 1982, pages 1413 - 1424 |
See also references of EP4325210A4 |
ŽALOUDíKOVá MARIE; VYTášEK RICHARD; RAšKOVá MARCELA; VíZEK MARTIN; UHLíK JIř: "The effect of exposure to hypoxia on superoxide formation by alveolar macrophages is indirect", LIFE SCIENCE, PERGAMON PRESS, OXFORD, GB, vol. 236, 10 September 2019 (2019-09-10), GB , XP085873770, ISSN: 0024-3205, DOI: 10.1016/j.lfs.2019.116864 * |
Also Published As
Publication number | Publication date |
---|---|
TW202307174A (zh) | 2023-02-16 |
EP4325210A1 (en) | 2024-02-21 |
JPWO2022220288A1 (ja) | 2022-10-20 |
US20240043742A1 (en) | 2024-02-08 |
EP4325210A4 (en) | 2024-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2088434B1 (en) | Pyrocatechol violet-metal protein assay | |
JP2019515251A (ja) | 電気化学発光検出における分枝鎖アミン | |
CN111855996A (zh) | 一种能提高吖啶酯抗原抗体结合物稳定性并降低本底的稀释液及其制备方法 | |
WO2022220288A1 (ja) | 組成物、安定化方法、および、発光量を測定する方法、ならびに、発光基質用安定化剤 | |
US10961185B2 (en) | Stabilizer and stabilization method | |
JP3702476B2 (ja) | 化学発光測定方法 | |
JP3711544B2 (ja) | 化学発光測定試薬 | |
JP6672353B2 (ja) | 免疫測定方法及びそれに用いられる免疫測定用キット | |
JP3711543B2 (ja) | 化学発光測定試薬及び測定方法 | |
JP2010117244A (ja) | ヘモグロビンの測定方法および測定用キット | |
JPH06165696A (ja) | 過酸化物分解性物質測定用指示薬および試薬キット | |
JPWO2019168109A1 (ja) | 検体中に含まれる蛋白質を安定化する方法、検体中に含まれる蛋白質を安定化させるための溶液 | |
CN118091145B (zh) | 一种吖啶酯结合物浓缩液和工作液及其应用 | |
JP3983909B2 (ja) | 感作金属コロイド試薬溶液の安定化方法及び該安定化試薬溶液 | |
JP2535290B2 (ja) | 過酸化物分解性物質測定用指示薬 | |
JP6857939B2 (ja) | 免疫学的測定方法および測定試薬 | |
JP6782785B2 (ja) | 免疫学的測定方法および測定試薬 | |
JP2020180915A (ja) | 免疫測定の検体前処理用試薬及び検体前処理方法、並びに免疫測定用キット | |
JP3839133B2 (ja) | 安定化された化学発光試薬 | |
JPH0889291A (ja) | 過酸化物分解性物質測定用指示薬および試薬キット | |
JP2021071475A (ja) | 免疫測定方法及び免疫測定用キット | |
JPH05227995A (ja) | 過酸化物分解性物質測定用指示薬および試薬キット | |
JPH0622794A (ja) | 過酸化物分解性物質測定用指示薬および試薬キット | |
CN118169401A (zh) | 一种雄烯二酮检测试剂盒及检测方法 | |
JP2022156263A (ja) | 免疫測定用試薬、免疫測定用キット及び免疫測定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22788211 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023514683 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022788211 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022788211 Country of ref document: EP Effective date: 20231116 |